EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, iX Biopharma's enterprise value is S$32.96 Mil.
iX Biopharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was S$-7.05 Mil. Therefore, iX Biopharma's EV-to-EBITDA for today is -4.68.
The historical rank and industry rank for iX Biopharma's EV-to-EBITDA or its related term are showing as below:
SGX:42C'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -43.87 Med: -17.78 Max: -3.34
Current: -4.68
During the past 10 years, the highest EV-to-EBITDA of iX Biopharma was -3.34. The lowest was -43.87. And the median was -17.78.
SGX:42C's EV-to-EBITDA is ranked worse than 100% of 708
companies
in the Drug Manufacturers industry
Industry Median: 14.075
vs SGX:42C: -4.68
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
iX Biopharma EV-to-EBITDA Historical Data
The historical data trend for iX Biopharma's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of iX Biopharma's EV-to-EBITDA
For the Drug Manufacturers - Specialty & Generic subindustry, iX Biopharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
iX Biopharma's EV-to-EBITDA Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, iX Biopharma's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where iX Biopharma's EV-to-EBITDA falls into.
iX Biopharma EV-to-EBITDA Calculation
iX Biopharma's EV-to-EBITDA for today is calculated as:
iX Biopharma's current Enterprise Value is S$32.96 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. iX Biopharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was S$-7.05 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
iX Biopharma (SGX:42C) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
iX Biopharma's PE Ratio for today is calculated as:
iX Biopharma's share price for today is S$0.041.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. iX Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was S$-0.013.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of iX Biopharma's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company focused on the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. Its products under development are Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, WafeRest for improved sleep quality, and others. Its business segments are Specialty Pharmaceutical and Nutraceutical business segments. The firm's business segments operate in United States of America, Singapore, Australia, and China, of which the majority of the revenue comes from the United States of America. The company generates the majority of its revenue from the sale of specialty pharmaceutical products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SGX:42C has been successfully added to your 